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Ramucirumab With Eribulin Versus Eribulin in
Locally Recurrent or Metastatic Breast Cancer
Previously Treated With Anthracycline and
Taxane Therapy: A Multicenter, Randomized,
Phase II Study
Denise A. Yardley,1 James Reeves,2 E. Claire Dees,3 Cynthia Osborne,4
Devchand Paul,5 Foluso Ademuyiwa,6 Hatem Soliman,7 Troy Guthrie,8
Jay Andersen,9 Lea Krekow,10 Janak Choksi,11 Brooke Daniel,12 Michael Danso,13
Anne Favret,14 Sanjay Oommen,15 Adam Brufsky,16 Jane L. Bromund,17
Yong Lin,17 Ayman B. Ibrahim,18 Paul D. Richards19
Abstract
We describe the efﬁcacy and safety of ramucirumab with eribulin versus eribulin monotherapy as third- to ﬁfthline therapy in women with advanced breast cancer. The primary end point of progression-free survival was not
met. Screening for brain metastases upon trial entry showed an unanticipated prevalence of asymptomatic
brain disease, raising new considerations for screening in late-stage metastatic breast cancer irrespective of
HER2 or hormone receptor status.
Background: Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We
evaluated the efﬁcacy and safety of ramucirumab and eribulin versus eribulin alone as third- to ﬁfth-line therapy in
women with advanced breast cancer. Patients and Methods: In this randomized (1:1), open-label, phase II study, US
women aged 18 years or older with 2 to 4 previous chemotherapy regimens for locally recurrent or MBC, previous
anthracycline and taxane treatment, and Eastern Cooperative Oncology Group performance status of 0 or 1 received
ramucirumab with eribulin or eribulin alone in 21-day cycles (eribulin 1.4 mg/m2 intravenously on days 1 and 8;
ramucirumab 10 mg/kg intravenously on day 1). Randomization was stratiﬁed according to previous antiangiogenic
therapy and triple-negative status. The primary end point was progression-free survival (PFS) in the intention to treat
population. Results: One hundred forty-one women were randomized to ramucirumab with eribulin (n ¼ 71) or eribulin
alone (n ¼ 70). Median PFS for ramucirumab with eribulin was 4.4 months (95% conﬁdence interval [CI], 3.1-6.7)
compared with 4.1 months (95% CI, 3.2-5.6) for eribulin (hazard ratio [HR], 0.83; 95% CI, 0.56-1.23; P ¼ .35). Median
overall survival in patients who received ramucirumab with eribulin was 13.5 months (95% CI, 10.4-17.9) compared
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with 11.5 months (95% CI, 9.0-17.3) in patients who received eribulin alone (HR, 0.91; 95% CI, 0.59-1.41; P ¼ .68);
objective response rate was 21% (13 of 62 patients) for the combination and 28% (17 of 60 patients) for eribulin alone.
No unexpected toxicity was identiﬁed for the combination. Conclusion: Ramucirumab combined with eribulin did not
signiﬁcantly improve PFS in advanced MBC.
Clinical Breast Cancer, Vol. 16, No. 6, 471-9 ª 2016 The Author(s). Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Antiangiogenic therapy, Brain metastasis, Targeted agents, Triple-negative status, VEGFR-2
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In 2016, in the United States, more than 240,000 women will be
diagnosed with breast cancer and approximately 40,000 deaths will
occur from metastatic breast cancer, with a 25% 5-year survival
estimated for women of all races.1 The pursuit of beneﬁcial therapeutic regimens for metastatic breast cancer has been a compelling
campaign in the oncology community. In human breast cancer,
intensive neovascularizations and tumor angiogenesis correlate with
metastases and poor prognosis.2,3
Strong preclinical and clinical evidence suggests vascular endothelial growth factor (VEGF) and angiogenesis play key roles in
breast cancer growth, invasion, and metastasis; this evidence paired
with strategies of VEGF inhibition showed improved outcomes in
early preclinical models.4,5 However, antiangiogenesis strategy success in other tumor types, including lung, cervical, colorectal,
glioblastoma, and renal cancers,6-10 has yet to be clearly replicated in
metastatic breast cancer. After more than a decade of unsuccessful
attempts to show an overall survival advantage,11-15 there is
currently no approved US indication for bevacizumab in breast
cancer, despite evidence of improved disease control, measured
according to response and progression-free survival, when combined
with single-agent chemotherapy.
Ramucirumab is a US Food and Drug Administration (FDA)approved, recombinant human monoclonal antibody that binds the
extracellular domain of VEGF receptor (VEGFR)-2, where it blocks
receptor interaction with activating ligands (VEGF-a, VEGF-C, and
VEGF-D), preventing downstream signaling involved in the formation and maintenance of aberrant blood vessels that supply tumors and maintain endothelial cell proliferation.16 Its selectivity for
VEGFR-2 sets it apart from the ligand-binding function of
bevacizumab. Global phase III trials in breast, gastric, lung, hepatocellular, and colorectal cancers were undertaken, leading to
ramucirumab’s ﬁrst FDA approval in 2014 as a single-agent treatment, or in combination with paclitaxel, for patients with advanced
or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression during or after ﬂuoropyrimidine- or
platinum-containing chemotherapy.17,18 Despite the efﬁcacy of
ramucirumab in gastric cancer, the recently reported Ramucirumab
Overall Survival Evaluation/Translational Research In Oncology-12
(ROSE/TRIO-12) study, a randomized, placebo-controlled, phase
III trial of ﬁrst-line docetaxel with ramucirumab versus docetaxel in
metastatic breast cancer, did not meet its primary end point of
progression-free survival.19
Eribulin is a nontaxane microtubule polymerization inhibitor
with clinical efﬁcacy and an acceptable toxicity proﬁle that is FDAapproved as a single agent in patients with metastatic breast cancer
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previously treated with an anthracycline and a taxane.20,21
Considering the observed efﬁcacy of eribulin in late-stage breast
cancer as well as in taxane- and anthracycline-pretreated metastatic
breast cancer coupled with the potential contribution of
VEGFRe2-mediated pathways in breast cancer pathogenesis,12-15
the combination of ramucirumab with eribulin was hypothesized
to improve clinical outcomes in advanced metastatic breast cancer.
Because of the published efﬁcacy of bevacizumab in metastatic
breast cancer studies,22,23 including use in combination with
paclitaxel, the ramucirumab with eribulin combination was
hypothesized to be active in metastatic breast cancer.
The primary objective of this randomized, open-label, phase II
study was to identify whether the combination of ramucirumab
with eribulin would increase progression-free survival compared
with eribulin alone, as third- to ﬁfth-line therapy in patients with
advanced breast cancer.

Patients and Methods
Study Design and Participants
This was a multicenter, randomized, open-label, phase II trial
conducted at 44 centers in the United States. Female patients aged
18 years or older with stage III locally recurrent not amenable to
curative therapy or stage IV metastatic breast cancer and 2 to 4
previous chemotherapy regimens in the advanced setting were
eligible for enrollment. Previous anthracycline and taxane treatment, previous HER2-directed treatment in HER2-positive disease
(unless contraindicated), normal left ventricular ejection fraction,
and Eastern Cooperative Oncology Group performance status of
0 or 1 were required. Patients were eligible for inclusion if they had
measurable and/or nonmeasurable disease deﬁned using Response
Evaluation Criteria in Solid Tumors version 1.1 (RECIST). Key
exclusion criteria included uncontrolled hypertension, bevacizumab
administration within 6 weeks, or a Grade  3 bleeding or venous
thromboembolic event within 3 months before randomization.
Patients with untreated and unstable central nervous system metastases within 3 months were also excluded; baseline brain imaging
was required for all patients and treated brain lesions had to show no
progression for  3 months.
The US study was approved by ethics review boards for each
center, and study conduct was guided by the Guideline for Good
Clinical Practice and the Declaration of Helsinki. Patients provided
written informed consent before initiation of treatments.

Randomization and Masking
Patients were randomized (1:1) via a call-in interactive voice
response system. Randomization was stratiﬁed according to

Denise A. Yardley et al
previous antiangiogenic therapy and triple-negative status (estrogen
receptor-negative, progesterone receptor-negative, and HER2negative). This was an open-label study; therefore, patients, medical staff, investigators, and funders were unmasked to the treatment assignment.

Study Treatment and Assessments
Female patients received ramucirumab 10 mg/kg intravenously
on day 1 with eribulin 1.4 mg/m2 intravenously on days 1 and 8, or
eribulin alone (1.4 mg/m2 on days 1 and 8). The cycle was repeated
every 3 weeks (21 days) until disease progression, development of
disease progression, development of unacceptable toxicity, withdrawal of consent, or other withdrawal criteria were met. Dose
modiﬁcations were permitted, but not required, for ramucirumab
in the setting of nonelife-threatening, reversible Grade 3-4 adverse
events that resolved to Grade  1 within 1 cycle. A second dose
reduction to 6 mg/kg every 3 weeks was permitted for Grade 3-4
events. Ramucirumab was to be discontinued for Grade 3-4 events
of hemorrhage, thromboembolism, or infusion-related reaction, and
Grade 4 hypertension. Eribulin dose modiﬁcations were made according to the manufacturer’s package insert.21 Ramucirumab and/
or eribulin was allowed to continue if toxicity was considered by the
investigator to not be related to that drug in the combination
group.
The changes in tumor size in post-treatment tumor assessments
were analyzed every 6 weeks. Imaging studies were undertaken every
6 weeks after the ﬁrst dose until documented disease progression.
Safety was analyzed for all patients who received at least 1 dose of
study treatment. A Safety Assessment Committee monitored the
study, including review of the safety cohort data for the ﬁrst 6 and
then 12 patients who received 2 cycles of combination therapy. The
safety and tolerability of ramucirumab and eribulin were determined
by reported adverse events, physical examinations, and laboratory
tests. Safety data were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Causality relationship to study drug was separately summarized.

Outcomes
The primary outcome was to compare the antitumor activity
between ramucirumab and eribulin or eribulin alone, measured
according to progression-free survival and deﬁned as the time
from the date of randomization until the date of objective progression deﬁned according to RECIST, or death from any cause,
whichever occurred ﬁrst. Secondary efﬁcacy outcomes included
overall survival, deﬁned as time from randomization to date of
death from any cause; objective response rate, deﬁned as the
proportion of patients achieving a best overall response of partial
or complete response, determined for patients with measurable
disease according to RECIST; duration of response, measured
from the time measurement criteria were ﬁrst met for complete
response/partial response (whichever was ﬁrst recorded) until the
ﬁrst date at which the criteria for progressive disease were met
(taking as a reference for progressive disease the smallest measurement recorded since the treatment started), or until death; and
change in tumor size in patients with measurable disease at 6-week
assessments; as well as to assess the safety and tolerability of
ramucirumab with eribulin.

Statistical Analyses
The intention to treat population consisted of all eligible
randomized patients, regardless of study drug administration.
Assuming an increase in median progression-free survival from
3.7 months in the control group20 to 5.6 months in the experimental group, with 1:1 randomization, 110 progression-free survival
events (objective progression or deaths) conferred 80% power to
detect a hazard ratio (HR) experimental/control of 0.667 with a 2sided signiﬁcance level of 0.2. For the primary analysis, we
compared progression-free survival between the 2 treatment groups
using a stratiﬁed log rank test at a 2-sided signiﬁcance level of 0.2,
with triple-negative breast cancer status and previous antiangiogenic
therapy as stratiﬁcation factors. Progression-free and overall survival
were estimated using the KaplaneMeier method. For overall survival and duration of response, we used the same model as for the
primary analysis. The objective response rate in patients with
measurable disease in the experimental group was measured and
compared
with
the
control
group
using
the
CochraneManteleHaenszel test, adjusted for stratiﬁcation variables. A 2-sided 95% conﬁdence interval (CI) for the objective
response rate of each arm was calculated using Fisher exact test. The
percentage of patients in each group with duration of response > 12
weeks was presented with a 2-sided 95% CI.
Changes in tumor size were analyzed by calculating the log ratio
of tumor size at time of assessment to tumor size at baseline for each
patient. This measure was compared between treatment groups by
using an analysis of covariance using previous antiangiogenic therapy and triple-negative status as factors.
We used SAS version 8.2 or later (SAS Institute, Inc, Cary, NC).
This study was registered with ClinicalTrials.gov; NCT01427933.

Results
Patients
Patient enrollment began on November 11, 2011; the primary
data cutoff for efﬁcacy (progression-free survival, response) and
safety was September 11, 2013, and the ﬁnal data cutoff for overall
survival was July 31, 2014. Seventy-one patients in the ramucirumab with eribulin group and 70 patients in the eribulin group
were in the intention to treat population (Figure 1). Patients’
baseline characteristics were well balanced between the 2 groups
(Table 1). There was an unanticipated rate of asymptomatic brain
metastases discovered with required brain imaging at screening
(20%; 47 patients with brain metastasis of 234 screened), resulting
in a screen failure rate of 15% (34 of 234) for this criterion
(Figure 1; Table 2). In total, for the 47 patients with asymptomatic
brain lesions, 27 of 47 (57%) were in the estrogen receptor- and/or
progesterone receptor-positive group and 20 of 47 (43%) were in
the triple-negative breast cancer group, with only 2 patients also in
the HER2-positive group. Receptor status for the 13 randomized
patients was also summarized.

Efﬁcacy
Median progression-free survival was 4.4 months (95% CI,
3.1-6.7) in the ramucirumab with eribulin group versus 4.1 months
(95% CI, 3.2-5.6) in the eribulin group, resulting in a nonsigniﬁcant HR of 0.83 (95% CI, 0.56-1.23; P ¼ .35; Table 3). The HRs
were consistent across 4 subgroups analyzed (triple-negative status,
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Figure 1 Trial Proﬁle and Study Design. Female Patients With Locally Recurrent or Metastatic Breast Cancer After 2, but No More Than
4, Previous Chemotherapeutic Regimens in the Relapsed/Metastatic Setting Were Stratiﬁed According to Previous
Antiangiogenic Treatment and Triple Negative Receptor Breast Cancer Status, and Randomly Assigned at a 1:1 Ratio to
Ramucirumab With Eribulin or Eribulin Monotherapy and Assessed for Progression-Free Survival and Overall Survival

Assessed for eligibility
(n = 234)

Screen failed patients (n = 93;
34 with brain metastases)

Patients randomized (1:1 randomization)
(n = 141)

Ramucirumab With Eribulin
(n = 71)

ITT Population
(n = 141)

Eribulin
(n = 70)
Did not receive
treatment (n = 5)

Did not receive
treatment (n = 2)
Ramucirumab
bW
With Eribulin Safety Population
(n = 69)
(n = 134)

Progressive disease
Symptomatic deterioration
Death
Withdrawal of consent with follow-up
Withdrawal of consent without follow-up
Lost to follow-up
Adverse event
Other
Missing

n
40
8
1
2
3
0
6
9
2

Treatment
discontinuation

previous antiangiogenic therapy, visceral vs. nonvisceral sites of
metastasis, and number of metastatic sites), including the
prespeciﬁed stratiﬁcation factors of triple-negative breast cancer
status and previous antiangiogenic therapy status (Figure 2), noting
that the study was not powered for subgroup survival analysis. The
reported subgroup results numerically favored the ramucirumab
combination, with the triple-negative subgroup showing a large
beneﬁt. The median overall survival for the ramucirumab with
eribulin group was 13.5 months (95% CI, 10.4-17.9) versus 11.5
months (95% CI, 9.0-17.3) in the eribulin group; the HR was 0.91
(95% CI, 0.59-1.41; P ¼ .68; Table 3).
Thirteen of 62 patients with measurable disease in the ramucirumab with eribulin group versus 17 of 60 patients in the eribulin
group had a partial response, resulting in an objective response rate
of 21% (95% CI, 11.7-33.2) versus 28% (95% CI, 17.5-41.4;
P ¼ .39; Table 4). The median duration of response in the
intention to treat population was 5.5 months (95% CI, 3.1-7.1) in
the ramucirumab with eribulin group and 3.0 months (95% CI,
1.4-4.4) in the eribulin group; the 6-month rate for patients with
response was 39.0% versus 7.1%, with a treatment effect difference
of 31.8% (95% CI, 2.1-61.6). An overall reduction in tumor size in
both treatment arms was seen after the 6-week tumor assessment
(ramucirumab with eribulin: 61% [43 of 71]; eribulin 56% [39 of
70]). The reduction in tumor size up to 36 weeks was similar.
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E ib
Eribulin
(n = 65)

n
Progressive disease
37
37
7
Symptomatic deterioration
7
0
Death
0
4
Withdrawal of consent with follow-up
4
4
Withdrawal of consent without follow-up
4
0
Lost to follow-up
0
3
Adverse event
3
12
Other
12
3
Missing
3

Safety
All-cause treatment-emergent adverse events in  20% of
patients and Grade  3 (in  5% of patients) events are listed in
Table 5. Overall, there were more events reported in the ramucirumab with eribulin group than in the eribulin group. Treatmentemergent adverse events (any grade) reported more frequently
(P < .05) in the ramucirumab with eribulin group (n ¼ 69) than in
the eribulin group (n ¼ 65) were headache (27 [39%] vs. 10 [15%])
and pyrexia (14 [20%] vs. 5 [8%]). Other than neutropenia and
fatigue (known adverse events for eribulin and ramucirumab), most
were low-grade events.
Data on treatment-emergent adverse events of special interest
were collected, for safety monitoring purposes, on the basis of
previously reported adverse events associated with antiangiogenic
agents and other therapeutic monoclonal antibodies. Events of
special interest of any grade were reported more frequently in the
ramucirumab with eribulin group than in the eribulin group (see
Supplemental Table 1 in the online version). Hypertension and
bleeding were the most frequently reported (P < .05) events of
special interest in patients who received ramucirumab (9 of 69
[13%] vs. 1 of 65 [2%] and 13 of 69 [19%] vs. 3 of 65 [5%],
respectively). Bleeding events in patients treated with ramucirumab
with eribulin included 7 Grade 1 epistaxis events and 1 Grade 3
gastrointestinal hemorrhage.
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Table 1 Baseline Demographic and Clinical Characteristics in
the Intention to Treat Population
Characteristic

Ramucirumab With
Eribulin (n [ 71)

Eribulin
(n [ 70)

Age, Years
Median (range)

Table 2 Tumor Receptor Status Characteristics for Patients
With Baseline or History of Brain Metastases
Receptor Status
Patients With Brain Metastases

57 (32-78)

56 (32-84)

þ

ER and/or PR

þ

þ

Screen Failure
(n [ 93), n

Enrolled
(n [ 141), n

34

13a

21

6

b

18-64

62 (87)

53 (76)

HER2

2

0

65

9 (13)

17 (24)

TNBC

13

7

White

54 (76)

58 (83)

Black or African American

Race
11 (15)

8 (11)

Other

5 (7)

2 (3)

Asian

1 (1)

American Indian or Alaska Native

0

1 (1)
1 (1)

ECOG PS
0

36 (51)

37 (53)

1

35 (49)

32 (46)

2

0

1 (1)

Previous Chemotherapy in
Relapsed/Metastatic Setting
Patients with 1 line

71 (100)

66 (94)

Patients with 2 lines

69 (97)

63 (90)

Patients with 3 lines

33 (46)

29 (41)

Patients with 4 lines

10 (14)

7 (10)

Yes

21 (30)

22 (31)

No

50 (70)

48 (69)

Randomization Stratum
Triple negative receptor status

Previous antiangiogenic therapy
Yes

24 (34)

26 (37)

No

47 (66)

44 (63)

ERþ/PRþ

34 (48)

34 (49)

ERþ/PR

12 (17)

10 (14)

ER/PRþ

2 (3)

1 (1)

ER /PR

23 (32)

25 (36)

HER2þ

6 (8)

6 (9)

79.6 (55.4)

85.4 (64.0)

Receptor status





Mean Duration of Disease (SD),
Months

Data are presented as n (%) except where otherwise noted.
Abbreviations: ECOG PS ¼ Eastern Cooperative Oncology Group performance status; ER ¼
estrogen receptor; PR ¼ progesterone receptor.

For the ramucirumab with eribulin group, 69 patients received at
least 1 dose of ramucirumab with a median of 4 infusions (interquartile range [IQR], 2-7), median dose intensity of 3.3 mg/kg/wk
(IQR, 3.0-3.3), and median relative dose intensity of 99.1% (IQR,
91.2%-100.5%); with eribulin, there was a median of 9 infusions
(IQR, 4-15), median dose intensity of 0.8 mg/m2/wk (IQR,
0.7-0.8), and median relative dose intensity of 83.5% (IQR,
72.9%-90.8%). In the eribulin group, 65 patients received at least 1
dose of eribulin, with a median of 10 infusions (IQR, 4-15), median
dose intensity of 0.8 mg/m2/wk (IQR, 0.6-0.8), and median relative
dose intensity of 81.6% (IQR, 69.2%-90.0%). The overall extent of
eribulin exposure was similar in both treatment groups.

Abbreviations: ER ¼ estrogen receptor; PR ¼ progesterone receptor; TNBC ¼ triple-negative
breast cancer.
a
Early in the conduct of the study, 13 patients were randomized having either treated and stable
brain lesions, or protocol violations. Many were discovered randomized for whom baseline brain
imaging was not completed. When these errors were found, usually within the ﬁrst cycle, the
patients immediately underwent “delayed” brain imaging and, at times, a brain lesion was
found. The study reported on the intention to treat population and patients with protocol violations were still included in the analysis.
b
The 2 patients with HER2þ tumors also were ERþ and PRþ.

Treatment-emergent adverse events resulting in at least 1 dose
delay or modiﬁcation occurred in 38 of 69 patients (55%) treated
with ramucirumab with eribulin and in 30 of 65 patients (46%)
treated with eribulin. Across both treatment groups, the most
frequently reported events leading to delay/modiﬁcation of any
study drug were fatigue, neutropenia, and neuropathy.
Ramucirumab-related adverse events in 8 of 69 patients (12%) and
eribulin-related adverse events in 7 of 69 patients (10%) caused dose
discontinuations in the ramucirumab with eribulin group; 6 of 65
patients (9%) had dose discontinuations because of adverse events
in the eribulin monotherapy group.

Discussion
In this randomized, phase II study, ramucirumab 10 mg/kg every
3 weeks combined with eribulin did not signiﬁcantly improve
progression-free survival, overall survival, or objective response rate
as a third- to ﬁfth-line therapy in patients with metastatic breast
cancer. Not surprisingly, higher rates of fatigue, headache, hypertension, diarrhea, pyrexia, and bleeding were observed in the
ramucirumab with eribulin group; however, no unexpected toxicities were observed and the safety data were consistent with those
reported for ramucirumab in other trials.17,18,24-26
When this trial was designed, it was believed that ramucirumab
would particularly beneﬁt breast cancer patients, especially if biomarkers could be identiﬁed that would delineate those most likely to
beneﬁt from antiangiogenic therapies. Antiangiogenic agents in the
treatment of metastatic breast cancer remain controversial, with
conﬂicting results regarding their overall effect on survival and the
inability to predict which patient subpopulation might derive
meaningful beneﬁt. Similar to the results seen with the lower dose in
the docetaxel/bevacizumab-based AVADO (Avastin And Docetaxel)
trial,12 a statistically nonsigniﬁcant numerical improvement in
progression-free survival was seen in the ramucirumab/docetaxel
group, whereas a signiﬁcant improvement in objective response rate,
disease control rate, and time to progression was seen in the ROSE
trial.19 A companion analysis of potential predictive biomarkers in
the ROSE study and the present metastatic breast cancer phase II
study is pending that might potentially identify a patient subpopulation for whom a ramucirumab treatment strategy in breast cancer
is beneﬁcial.

Clinical Breast Cancer December 2016

- 475

Ramucirumab With Eribulin Versus Eribulin in Breast Cancer
Table 3 Progression-Free and Overall Survival in the Intention to Treat Population
Ramucirumab With
Eribulin (n [ 71)
Median Progression-Free Survival, Months (95% CI)
Median Overall Survival, Months (95% CI)

Eribulin
(n [ 70)

P (Stratiﬁed
Log Rank)

HR
(95% CI)

4.4 (3.1-6.7)

4.1 (3.2-5.6)

0.83 (0.56-1.23)

.35

13.5 (10.4-17.9)

11.5 (9.0-17.3)

0.91 (0.59-1.41)

.68

Disposition
Deaths

47 (66)

42 (60)

Censored

24 (34)

28 (40)

Alive

18 (25)

20 (29)

6 (8)

8 (11)

Withdrawal of consent
Data are presented as median (95% CI) or n (%), except where otherwise noted.
Abbreviation: HR ¼ hazard ratio.

Despite the lack of signiﬁcant improvements in progression-free
survival with the combination of ramucirumab in the recent metastatic breast cancer studies, other solid tumor trials highlight the
efﬁcacy and safety of ramucirumab.17,18,24-26 The phase III REVEL
(ramucirumab plus docetaxel versus placebo plus docetaxel for
second-line treatment of stage IV non-small-cell lung cancer after
disease progression on platinum-based therapy) trial, using the same

dose and schedule of ramucirumab combined with docetaxel as in
the ROSE trial, signiﬁcantly prolonged survival in patients with
stage IV nonesmall-cell lung cancer, compared with those treated
with docetaxel alone, and led to FDA approval in the United
States.25 In addition, the placebo-controlled, phase III REGARD
(ramucirumab monotherapy for previously treated advanced gastric
or gastro-oesophageal junction adenocarcinoma) and RAINBOW

Figure 2 Forest Plot for Subgroup Analyses of Progression-Free Survival. Hazard Ratio (HR) and 95% CI Were Estimated From
Unstratiﬁed Cox Model. Horizontal Bars Represent 95% CI
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Table 4 Overall Tumor Response in Patients With Measurable
Disease
Ramucirumab
With Eribulin
(n [ 62)

Response

Eribulin
(n [ 60)

Best Overall Response, n (%)a
CR

0

0

PR

13 (21)

17 (28)

SD

27 (44)

21 (35)

PD

13 (21)

14 (23)

1 (2)

0 (0)

Not evaluable
CR D PR D SD ‡12 Weeks,
n (%) (95% CI)

30 (48) (35.5-61.4) 25 (42) (29.1-55.1)

Objective Response Rate (CR
D PR), n (%) (95% CI)

13 (21) (11.7-33.2) 17 (28) (17.5-41.4)

a

Response data were not available for 8 patients who received ramucirumab with eribulin (13%)
and 8 patients who received eribulin (13%).

(ramucirumab as a single agent, or in combination with paclitaxel,
in patients with advanced or metastatic gastric or gastroesophageal
junction adenocarcinoma with disease progression on or after prior
ﬂuoropyrimidine- or platinum-containing chemotherapy) studies
led to the FDA approval of ramucirumab either as a single agent at 8

Table 5 All-Cause TEAEs ‡ 20% or Grade ‡ 3 (‡ 5%)
Selected Safety
Ramucirumab With
Eribulin (n [ 69)
TEAE
Fatigue
Neutropenia
Nausea
Headache
Constipation
Decreased
Appetite
Alopecia
Vomiting
Diarrhea
Dyspnea
Peripheral
Sensory
Neuropathy
Anemia
Pyrexia
Dehydration
Neutrophil
Count
Decreased
Leukopenia

Any Grade Grade ‡3
(‡20%)
(‡5%)

Eribulin (n [ 65)
a

Any Grade Grade ‡3a
(‡20%)
(‡5%)

44
29
28
27
20
20

(64)
(42)
(41)
(39)b
(29)
(29)

11
27
2
1
0
1

(16)
(39)
(3)
(1)
(0)
(1)

37
29
27
10
19
12

(57)
(45)
(42)
(15)
(29)
(18)

4
24
0
0
0
0

(6)
(37)
(0)
(0)
(0)
(0)

20
19
17
15
15

(29)
(28)
(25)
(22)
(22)

0
2
1
3
4

(0)
(3)
(1)
(4)
(6)

15
17
10
14
16

(23)
(26)
(15)
(22)
(25)

0
0
1
0
3

(0)
(0)
(2)
(0)
(5)

14
14
12
6

(20)
(20)b
(17)
(9)

3
0
6
4

(4)
(0)
(9)
(6)

16
5
7
8

(25)
(8)
(11)
(12)

3
0
1
5

(5)
(0)
(2)
(8)

4 (6)

2 (3)

8 (12)

7 (11)

Data are presented as n (%).
Abbreviation: TEAE ¼ treatment-emergent adverse event.
a
There were 2 Grade 5 events (1 septic shock and 1 acute renal failure) in the ramucirumab
group and 1 subdural hematoma in the eribulin group.
b
P < .05 for between treatment group comparison, on the basis of Fisher exact test.

mg/kg every 2 weeks or in combination with paclitaxel in patients
with advanced gastric or gastroesophageal junction adenocarcinoma
whose disease had progressed despite ﬂuoropyrimidine- or
platinum-containing chemotherapy.17,18 Also, a signiﬁcant overall
survival and progression-free survival advantage was noted with the
combination of ramucirumab with FOLFIRI (folinic acid, 5-ﬂuorouracil, irinotecan) in the RAISE (ramucirumab in combination
with FOLFIRI in patients with metastatic colorectal cancer with
disease progression on or after prior therapy with bevacizumab,
oxaliplatin, and a ﬂuoropyrimidine) trial, which evaluated ramucirumab as second-line therapy for patients with metastatic colorectal carcinoma in whom ﬁrst-line oxaliplatin-based chemotherapy
with bevacizumab had failed.26 In all patient populations, including
those in the current study, ramucirumab resulted in predictable and
manageable toxicities.17,18,24-26
Cancer biology remains complex, with different tumor types
showing varied responses. Ultimately, it is critical to understand
the tumor biology and, perhaps, individual patient characteristics that will allow determination and prediction of clinical
beneﬁt with a VEGF strategy, which currently remains elusive.
This randomized, phase II trial had several inherent limitations.
The study population in this trial was a heterogenous group,
with heavily pretreated patients. Therapy tested in patients who
receive later lines of therapy might be less effective because of
the activation of a variety of resistance mechanisms, which are
poorly understood and might contribute to cancer progression.
Although there are numerous mechanisms of resistance, preclinical models of eribulin activity have shown that CD31,
which facilitates vascularization of capillary beds, and carbonic
anhydrase 9 (CA9), a hypoxia marker, both play roles in
capillary proliferation in hypoxic, poorly vascularized areas,
particularly tumor cores.27 However, although a decrease in
CA9 was seen in preclinical studies with eribulin exposure, an
advantage for eribulin with ramucirumab was not evident in
this study. Thus a clearer understanding of the biology of this
combination might provide further insight into this observed
lack of beneﬁt.
Drugs that seemingly demonstrate no overall beneﬁt might
beneﬁt subgroups of patients, but identifying these subsets remains
challenging. In this trial, all subgroup results were numerically in
favor of the ramucirumab combination (Figure 2). Thus, the ability
to select patients who might beneﬁt from antiangiogenic therapy
might be the key. Identiﬁcation of reliable biomarkers to assist in
the selection and evaluation of the activity of these agents remains
elusive, but might lead to the determination of reliable end points.
In this trial, ramucirumab treatment was assessed in an unselected patient population, which might have obscured its potential
beneﬁt in a subset population. Despite an extensive search for
biomarkers, no convincing candidates have been identiﬁed. In lung
and colon cancers, bevacizumab is more effective with select
chemotherapy pairing.7,28,29 Similarly, eribulin might not be the
optimal chemotherapeutic partner for ramucirumab.
Interestingly, our study had an unanticipated number of women
with asymptomatic brain metastases at screening, irrespective of the
underlying HER2 or hormone receptor status. Current National
Comprehensive Cancer Network guidelines specify brain magnetic
resonance imaging for suspicious central nervous system symptoms
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during a recurrent or stage IV workup.30 The prevalence of incidental asymptomatic brain disease in this study might prompt
considerations for future studies in metastatic breast cancer on the
role of screening and therapy for asymptomatic brain metastases in
late-stage metastatic breast cancer, regardless of tumor receptor
status.
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Conclusion
Metastatic breast cancer clinical trial results to date do not support the combination of ramucirumab at 10 mg/kg every 3 weeks
with chemotherapy. Questions remain as to whether the VEGF
pathway is a valid target in metastatic breast cancer and whether a
single-targeted agent is optimal to effectively inhibit VEGFmediated signaling. Furthermore, the VEGF pathway likely is not
unilaterally essential for cell proliferation, because of the existence of
parallel and escape pathways in tumors. Thus, it is imperative to
evaluate quantitative biomarkers of response to anti-VEGF strategies, as well as to develop an understanding of the molecular
mechanisms of activity and resistance. Perhaps insight might be
gained into an understanding of the chemosensitization effects at
the cellular and molecular levels and the likelihood that combinations of targeted agents will or will not be necessary to optimize
therapeutic efﬁcacy and to sufﬁciently affect these mechanisms.
Serial tumor biopsies to more comprehensively understand the
natural history spectrum of tumor biology at baseline and
throughout treatment are critical to advancing therapies for metastatic breast cancer. Only then might we expand and improve our
understanding of VEGF pathway inhibitors and reﬁne the use of
this targeted therapy in breast tumors.
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 Evidence suggests that angiogenesis plays a key role in breast
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cancer, and intensive neovascularizations and tumor angiogenesis
correlate with metastases and poor prognosis.
Ramucirumab is a human monoclonal antibody that inhibits
ligand activation of the VEGFR-2, and is currently approved by
the FDA for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma, metastatic colorectal cancer, and
metastatic nonesmall-cell lung cancer.
Eribulin is approved by the FDA as a single agent in patients
with metastatic breast cancer who were previously treated with
an anthracycline and a taxane.
The published efﬁcacy of bevacizumab in combination with
paclitaxel in metastatic breast cancer formed the rationale to
explore the ramucirumab with eribulin combination as third- to
ﬁfth-line therapy in women with advanced breast cancer.
In our multicenter, randomized, open-label, phase II trial of
ramucirumab with eribulin versus eribulin alone, the combination showed acceptable toxicity but failed to meet the primary
end point of improved progression-free survival.
Our study had an unanticipated number of women with
asymptomatic brain metastases at screening, irrespective of the
underlying hormone or HER2 receptor status.
Further research into the role of quantitative biomarkers of
response to anti-VEGF strategies, as well as developing an understanding of the molecular mechanisms of activity and resistance are required.
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Supplemental Table 1 Treatment-Emergent Adverse Events of Special Interest
Ramucirumab With Eribulin (n [ 69)
Event of Special Interest

Any Grade, n (%)

Arterial Thromboembolic Event
Bleedinga
Congestive Heart Failure
GI Hemorrhage Event
Healing Complication
Hypertension
Infusion-Related Reaction
Proteinuria
Renal Failure
Venous Thromboembolic Event

1
13
1
3
1
9
1
4
2
3

(1)
(19)b
(1)
(4)
(1)
(13)b
(1)
(6)
(3)
(4)

Grade ‡3, n (%)
1
1
1
1
1
3
0
0
2
2

(1)
(1)
(1)
(1)
(1)
(4)
(0)
(0)
(3)
(3)c

Abbreviation: GI ¼ gastrointestinal.
a
Values for ramucirumab with eribulin bleeding included 7 patients with epistaxis.
b
P < .05 for between treatment group comparison of any grade events on the basis of Fisher exact test.
c
Events were pulmonary emboli.
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Eribulin (n [ 65)
Any Grade, n (%)
0
3
0
0
0
1
0
3
1
2

(0)
(5)
(0)
(0)
(0)
(2)
(0)
(5)
(2)
(3)

Grade ‡3, n (%)
0
1
0
0
0
1
0
0
0
1

(0)
(2)
(0)
(0)
(0)
(2)
(0)
(0)
(0)
(2)c

